Scarica l'app Stockscreener
21.96
3.30%
-0.75
Precedente Chiudi:
$22.71
Aprire:
$22.745
Volume 24 ore:
286.29K
Relative Volume:
0.46
Capitalizzazione di mercato:
$1.62B
Reddito:
$81.26M
Utile/perdita netta:
$-102.66M
Rapporto P/E:
-16.05
EPS:
-1.3678
Flusso di cassa netto:
$-77.62M
1 W Prestazione:
-3.94%
1M Prestazione:
-15.99%
6M Prestazione:
-2.53%
1 anno Prestazione:
+74.84%
Intervallo 1D:
$21.80
$22.75
Intervallo di 1 settimana:
$21.80
$23.59
Portata 52W:
$11.51
$29.75
Zymeworks Inc. Stock (ZYME) Company Profile
Nome
Zymeworks Inc.
Settore
Industria
Telefono
604-678-1388
Indirizzo
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
21.96 | 1.69B | 81.26M | -102.66M | -77.62M | -1.3678 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-10-24 | Ripresa | Wells Fargo | Equal Weight |
| 2025-10-14 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Ripresa | Wells Fargo | Overweight |
| 2023-01-04 | Reiterato | H.C. Wainwright | Neutral |
| 2022-12-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
| 2022-05-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-03-15 | Iniziato | Evercore ISI | Outperform |
| 2021-12-10 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Neutral |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-02-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Ripresa | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-06 | Iniziato | SVB Leerink | Outperform |
| 2020-01-10 | Iniziato | Wolfe Research | Outperform |
| 2019-12-09 | Iniziato | JP Morgan | Neutral |
| 2019-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-30 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Iniziato | Stifel | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Iniziato | Raymond James | Outperform |
Mostra tutto
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Rubric Capital Management LP Acquires 1,250,000 Shares of Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc (ZYME) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zymeworks Inc (ZYME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zymeworks Inc (ZYME) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SummitTX Capital L.P. Purchases 97,159 Shares of Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc (ZYME) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zymeworks Inc (ZYME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zymeworks Inc (ZYME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zymeworks Inc (ZYME) Balance Sheet - TradingKey
TradingKey - TradingKey
Zymeworks Inc. Revenue Breakdown – LSX:A3DSSN - TradingView
Zymeworks Inc. (ZYME) Stock Analysis: A 70% Upside Potential Amidst Biotech Innovations - DirectorsTalk Interviews
ZYME|Zymeworks Inc|Price:22.860|Chg%:-0.260 - TradingKey
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 - Sahm
Zymeworks to report Q2 2026 financial results on August 6 - scanx.trade
Zymeworks Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026 - Quiver Quantitative
Zymeworks Won’t Host Q2 Call Amid Proposed Theravance Deal - Stock Titan
Truist Remains Bullish on Zymeworks (ZYME) – Here’s Why - Yahoo Finance
ETFs Investing in Zymeworks Inc. Stocks - TradingView
Hillsdale Investment Management Inc. Has $8.65 Million Stock Position in Zymeworks Inc. $ZYME - MarketBeat
Pictet Asset Management Holding SA Has $232,000 Stock Position in Zymeworks Inc. $ZYME - MarketBeat
Theravance stock down 3% after Zymeworks announces buyout - MSN
Zymeworks ZW49 from ZYMEantibody drug conjugate targets solid tumors - Ad-hoc-news.de
Zymeworks Inc outlines its biotech strategy as investors track clinical progress - ad-hoc-news.de
Zymeworks: A Deep Dive (NASDAQ:ZYME) - Seeking Alpha
Form 4 Zymeworks Inc For: 6 July By Investing.com - Investing.com Nigeria
Zymeworks (ZYME) COO acquires 939 ESPP shares at discounted $22.22 - Stock Titan
Price to book forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future - Kavout | AI
Zymeworks Q1 2026 presentation: zanidatamab nears FDA decision - Investing.com
Zymeworks (ZYME) Breaks Out: +2.29% Rally Tests Key Resistance Near $27.63Buffered ETF - dars.gov.et
Enterprise value to EBIT forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Zymeworks Inc outlines its antibody-drug conjugate strategy as investors watch oncology partnerships - Ad-hoc-news.de
Zymeworks Inc. (ZYME): Exploring the Potential of an Undervalued Biotech in OncologyEarnings Stability Report - dars.gov.et
ZYME Q1 2026 Earnings: Wide EPS Miss Amid No Revenue as Operating Losses DeepenReturn On Assets - dars.gov.et
Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) - Seeking Alpha
Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run - Yahoo Finance
Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks - Arthur Cox LLP
Enterprise value to revenue forward of Zymeworks Inc. – BOATS:ZYME - TradingView
The Zymeworks ZW25 bispecific antibodya flexible HER2 therapy option for oncology partners - ad-hoc-news.de
Canadian Zymeworks acquires American Theravance Biopharma for $929 million - AKM.RU
Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead? - Insider Monkey
After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion - The Business Journals
Zymeworks Inc. (ZYME) M&A CallSlideshow (NASDAQ:ZYME) 2026-06-30 - Seeking Alpha
Theravance Stock Down 3% After Zymeworks Announces Buyout - Yahoo Finance
Press Release: Zymeworks to Acquire Theravance Biopharma, Inc. - Moomoo
Zymeworks agrees to buy Theravance Biopharma for $929m - Pharmaceutical Technology
Zymeworks to buy troubled U.S.-Irish pharma company Theravance for US$929M - The Logic
Vancouver biotech Zymeworks buying Theravance for US$929M - Castanet
Zymeworks Inc to Acquire Theravance Biopharma Inc Transcript - GuruFocus
Zymeworks Inc. Stock 12‑Month Price Target Raised to $38.75, Implies 60% Upside - TradingView
Zymeworks Inc. Azioni (ZYME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):